arrow

Coherus Biosciences' Outsourcing Strategy

Originally published by Zymewire on 09/28/2014.

With Coherus Biosciences’  $86 Million IPO announced last week, we wanted to take a closer look at the companies that stand to benefit the most from the upcoming injection of capital.  On the contract research side, Medpace appears to be in a strategic position to block further CRO’s from getting the biosimilar study business (see graphic).  The contract manufacturing equation is more diverse with Cook, KBI, Rentschler, and Catalent all getting a piece of the action.  Two fill finish opportunities still exist as of the time of this blog post.  Check out the graphic for the the full breakdown.   

Diagram of Coherus BiosSciences outsourcing CRO CMO vendor strategy

Comments

Custom built for biotech and pharma

We are obsessed with finding new ways to help your business generate more qualified leads. Our human-verified AI scans thousands of documents every day, separates the signal from the noise, and delivers value in the form of actionable sales intelligence.